Disease- vs Target-Based Drug Discovery

December 6, 2012 | The former head of psychopharmacology at Boehringer Ingelheim, Frank Sams-Dodd, talks about the reason for pharma's decreased productivity, and the ways drug discovery are done that contribute to the problem. A disease-based drug discovery is undoubtedly cheaper, he contends, and it's also more productive. Yet target-based approaches are dominant in the industry. Pharmalot